EcoDrugPlus

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSTBEG00000017504
Gene Symbol: CCR1
1 Cross references
299 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSTBEG00000004629
Gene Symbol: CCR4
1 Cross references
254 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSTBEG00000010795
Gene Symbol: CXCL8
1 Cross references
183 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSTBEG00000007303
Gene Symbol: DNMT1
1 Cross references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSTBEG00000002481
Gene Symbol: TOP1
1 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSTBEG00000005319
Gene Symbol: TOP2A
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSTBEG00000014469
Gene Symbol: TOP2B
1 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSTBEG00000013511
Gene Symbol: EML4
1 Cross references
209 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSTBEG00000011879
Gene Symbol: EPHA2
1 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSTBEG00000011301
Gene Symbol: EPHA3
1 Cross references
215 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSTBEG00000007492
Gene Symbol: FAU
1 Cross references
178 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSTBEG00000007722
Gene Symbol: FYN
1 Cross references
261 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).